Key Takeaways
-
Imvionix acquired exclusive US and Canadian commercial rights to Beovu from Novartis, marking its first strategic transaction and commercial launch
-
Beovu is approved in both markets for wet AMD and DME, with Imvionix becoming the marketing authorization holder
-
Founded by former Alimera Sciences executives, Imvionix plans to focus on expanding the commercial reach of established retinal therapies
Imvionix has acquired exclusive commercial rights to Beovu (brolucizumab-dbll) from Novartis in the United States and Canada, marking the privately held biotechnology company's official commercial launch and its first strategic transaction.
Under the agreement, Imvionix will become the marketing authorization holder for Beovu in both countries. Financial terms were not disclosed.
Beovu is approved in the US and Canada for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
The acquisition establishes Beovu as the first product in Imvionix's commercial portfolio and supports the company's strategy of expanding access to established retinal therapies through a dedicated ophthalmology commercialization platform.
“We founded Imvionix because we believe there are proven retinal therapies where physicians and patients can further benefit from the focus and reach of a dedicated retina company,” said Rick Eiswirth, Founder and Chief Executive Officer of Imvionix. “Building on the strong foundation already established for BEOVU®, this acquisition exemplifies the type of opportunity Imvionix was built to pursue.”
Imvionix was founded in 2025 by Mr. Eiswirth, and other former Alimera Sciences executives Jason Werner, Todd Wood, and Elliot Maltz, in collaboration with Caligan Partners LP and Velan Capital.
Imvionix indicated that the transaction aligns with its broader strategy of identifying established retinal therapies that could benefit from focused commercialization.
